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Objective: To explore prognostic indicators of lung adenocarcinoma with leptomeningeal
metastases (LM) and provide an updated graded prognostic assessment model
integrated with molecular alterations (molGPA).
Methods: A cohort of 162 patients was enrolled from 202 patients with lung
adenocarcinoma and LM. By randomly splitting data into the training (80%) and
validation (20%) sets, the Cox regression and random survival forest methods were
used on the training set to identify statistically signiﬁcant variables and construct a
prognostic model. The C-index of the model was calculated and compared with that of
previous molGPA models.
Results: The Cox regression and random forest models both identiﬁed four variables,
which included KPS, LANO neurological assessment, TKI therapy line, and controlled
primary tumor, as statistically signiﬁcant predictors. A novel targeted-therapy-assisted
molGPA model (2022) using the above four prognostic factors was developed to predict
LM of lung adenocarcinoma. The C-indices of this prognostic model in the training
and validation sets were higher than those of the lung-molGPA (2017) and molGPA
(2019) models.
Conclusions: The 2022 molGPA model, a substantial update of previous molGPA
models with better prediction performance, may be useful in clinical decision making
and stratiﬁcation of future clinical trials.
Keywords: leptomeningeal metastases, lung adenocarcinoma, molGPA model, overall survival, targeted therapy
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such as random forests, is lacking. Therefore, this study aimed to
ﬁll this research gap and study the role of targeted therapy in the
prediction of lung adenocarcinoma with LM using both
conventional molGPA and random forest models.

INTRODUCTION
Leptomeningeal metastases (LM) refers to the seeding of tumor
cells within the subarachnoid space and leptomeninges. It occurs
in up to 10% of adult patients with solid tumors, especially
melanoma, breast cancer, and non-small cell lung cancer
(NSCLC) (1, 2). The incidence of LM as a devastating
complication of NSCLC is increasing, especially in patients
with targeted molecule-driven mutations (3, 4). Lung
adenocarcinoma, which is the main component of NSCLC, is
more likely to develop LM. Molecular targeted therapy has
shown antitumor activity in central nervous system metastases,
with median overall survival ranging from 1 to 3 months for
historical treatments and 3 to 11 months for new treatments
(4, 5). Therefore, patients with lung adenocarcinoma have a
greater risk of developing sequelae of advanced diseases in the
future, such as brain metastasis (BM) and LM. These trends,
coupled with the wide application of magnetic resonance
imaging (MRI), indicate that an increasing number of patients
will be diagnosed with LM in the next few years.
Some existing studies have focused on predicting the
occurrence of heterogeneous BM. The Radiation Therapy
Oncology Group (RTOG) database was used to generate the
recursive partitioning analysis (RPA) classes which were
modiﬁed in 2012 (modiﬁed RPA) (6–8). RPA is a prognostic
index that is divided into three classes based on age, Karnofsky
performance status (KPS), control of primary tumor, and
extracranial metastases (ECM). The graded prognostic
assessment (GPA) index was developed in 2007 and revised in
2017 to form a lung-molGPA model using age, KPS, ECM,
number of BM, and gene status to deﬁne four disease classes,
with median survival ranging from 3.0 to 14.8 months (9–12). In
2019, another molGPA model was developed to predict LM
using factors, such as KPS, ECM, and gene status (13).
In both the lung-molGPA (2017) and molGPA (2019)
models, gene mutation status was identiﬁed as a signiﬁcant
prognostic factor (11, 12). From a clinical perspective, gene
mutation status, which indicates molecular-targeted therapy,
also has a signiﬁcant impact on the treatment of EM and LM.
However, the efﬁcacy of third-generation targeted drugs has led
to revolutionary development compared to ﬁrst- or secondgeneration targeted therapeutic approaches (2–5, 14, 15).
According to the BLOOM and AURA studies (5, 14, 15), the
third-generation epidermal growth factor receptor (EGFR)tyrosine kinase inhibitor (TKI) resulted in a signiﬁcantly
improved median overall survival (OS) of 11.0-18.8 months
compared to even higher doses of ﬁrst- or second-generation
EGFR TKIs with a median OS of 3.1-6.2 months (2). The
differences in efﬁcacy between generations of targeted therapy
may affect the prediction efﬁciency of the molGPA models.
Therefore, in this study, we compared the effects of gene
mutation status and targeted therapy on survival, and
developed a novel 2022 lung-molGPA for the patients of lung
adenocarcinoma with LM.
To the best of our knowledge, no studies have been conducted
to predict the survival of lung adenocarcinoma with LM using
targeted therapy; moreover, the use of machine learning methods,
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METHODS
Study Design and Samples
The study was conducted in accordance with the principles of the
Declaration of Helsinki, and the protocol was approved by the
Medical Ethics Committee of Henan Provincial People’s Hospital
(approval number: 2017-28). All study participants provided
written informed consent for the research and publication.
We collected data from 202 lung adenocarcinoma patients
with LM, enrolled between April 2017 and January 2022, at
Henan Provincial People’s Hospital, Zhengzhou, China. The
inclusion criteria were as follows: (i) ≥ 18 years; (ii) diagnosis of
lung adenocarcinoma conﬁrmed by histopathology; and (iii) LM
diagnosis ascertained according to the NCCN guidelines and the
European Association of Neuro-Oncology-European Society for
Medical Oncology (EANO-ESMO) guidelines (16). According to
the Leptomeningeal Assessment in Neuro-Oncology (LANO)
neurological assessment in LM (Supplement Table 1) (17), all
patients underwent complete work up, including standardized
neurological examination, brain and spine MRI, CSF analysis,
during hospitalization. Patients with insufﬁcient clinical
information (n=29) or missing follow-up data (n=11) were
excluded. Finally, 162 patients were included in the study
cohort and randomly assigned to the training (80%, n = 130)
and validation (20%, n = 32) sets (Figure 1).
Baseline clinicopathological characteristics of each patient
were obtained from their medical records; they included age,
sex, smoking status, ECM, controlled primary tumor, clinical
presentations, KPS, gene proﬁles of EGFR mutation and ALK
alteration, ThinPrep cytologic test (TCT), and brain and spine
MRI. Treatments including TKI therapy, chemotherapy,
bevacizumab, surgery, radiotherapy, intrathecal chemotherapy,
and immune checkpoint inhibitors were included in the study.
Controlled primary tumor was deﬁned as remission or stable
disease, without any clinical, radiologic, or laboratory ﬁndings
suggestive of tumor progression at 2 months (6, 7, 18). The
overall survival (OS) was deﬁned as the time from diagnosis of
LM to death.

Statistical Analysis
Missing values were imputed for variables with small missing
proportion. Continuous variables, that is, CSF white blood cells,
protein, and glucose, were transformed by taking the logarithm.
Other continuous variables were categorized based on clinical
reasoning and statistical methods. KPS status was divided into 3
groups: < 60 (high-risk group), 60-70 (moderate-risk group), and
80-100 (low-risk group). Age was dichotomized using a 65-year
cutoff. Univariate Cox models were performed on the training set
(n = 130), covering baseline characteristics, clinical symptoms,
brain and spinal MRI, CSF analysis and treatment, to identify
statistically signiﬁcant variables. With signiﬁcant variables in
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FIGURE 1 | Flow diagram of the enrollment of patients with lung adenocarcinoma with LM, and pipeline of data analysis to get the 2022 molGPA score. LM,
leptomeningeal metastases; EANO-ESMO, European Association of Neuro-Oncology-European Society for Medical Oncology. KPS, Karnofsky performance status;
LANO, Leptomeningeal Assessment in Neuro-Oncology; TKI, tyrosine kinase inhibitor; GPA, Graded Prognostic Assessment.

with the lung-molGPA (2017, Supplemental Table 2) and
molGPA (2019) models (Supplemental Table 3) by taking the
average of the C-index values from the randomly split training
and validation sets 100 times. Missing values were imputed for
variables with small missing proportion using R package mice
with default settings (e.g., the number of multiple imputations is
5) (21). All analyses were conducted in R software using the mice
package (21) for multiple imputation, survival package (22) for
Cox model and C-index, and the randomForestSRC package (19,
20) for random forest. The R code for analysis is available on the
Github Page: https://github.com/Penncil/A-2022-Targetedtherapy-assisted-molGPA-.

the univariate analysis, a multivariate Cox model was ﬁtted to the
training set to select signiﬁcant predictors to construct the
prognostic model.
We further utilized the random survival forest method to
validate the selected predictors using the Cox model. In addition
to the clinical prediction because of the high variance bias tradeof capability, Random survival forests (19, 20) method is also
usually used to select the most important variables that are linked
with the time-to-event outcome (i.e., OS). Given these
advantages of random survival forests, we ﬁrst utilized all
variables in the model to identify those with positive
importance values. With the top variables, we performed the
random survival forest method again to select signiﬁcant
variables, and compared them with those from the Cox model.
Furthermore, the C-index of the prognostic model constructed
using the top variables was calculated.
We constructed a novel molGPA model (2022) using
statistically signiﬁcant variables. The model was then used to
predict the OS of LM with lung adenocarcinoma cancer. The
C-index of the prognostic model was calculated and compared

Frontiers in Oncology | www.frontiersin.org

RESULTS
Clinicopathological Characteristics
of the Patients
The baseline clinical characteristics of patients in the training
and validation cohorts are presented in Table 1. There were no
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TABLE 1 | Demographic and clinical characteristics of the 162 lung adenocarcinoma patients with LM.
Characteristic

Age
≤65
>65
Sex
Male
Female
Smoke
No
Yes
Median time diagnosis to LM (median, range)
Clinical symptoms
Headache
Abnormal levels of consciousness and behavior
Cognitive impairment
Epilepsy
Cranial neuropathies
Spinal neuropathies
KPS at diagnosis of LM
<60
60-70
80-100
Gene status*
EGFR/ALK mutation
Wild type
Unknown
LANO neurological assessment
≥6
3-5
≤2
Extracranial metastases
No
Yes
Brain metastasis
No
Yes
Controlled primary tumor
No
Yes
Thinprep cytologic test*
Positive
Negative/Unknown
Brain and spinal MRI*
Positive
Negative
TKI therapy line
≤2nd
3rd
Treatments before LM
TKIs
Chemotherapy
Bevacizumab
Without treatments
Treatments for LM
TKIs
Chemotherapy
Bevacizumab
Operation
Radiotherapy
Intrathecal chemotherapy
Immunotherapy

Patients, No. (%)

p-value

Training set (n = 130)

Validation Set (n = 32)

90 (69.2)
40 (30.8)

25 (78.1)
7 (21.9)

57 (43.8)
73 (56.2)

16 (50.0)
16 (50.0)

95 (73.1)
35 (26.9)
10 (0, 120)

23 (71.9)
9 (28.1)
6 (0, 100)

97
35
25
26
41
13

(74.6)
(26.9)
(19.2)
(20.0)
(31.5)
(10.0)

21 (65.7)
7 (21.9)
4 (12.5)
9 (28.1)
12 (37.5)
2 (6.3)

50 (38.5)
42 (32.3)
38 (29.2)

7 (21.9)
13 (40.6)
12 (37.5)

103 (79.2)
13 (10.0)
14 (10.8)

25 (78.1)
6 (18.8)
1 (3.1)

34 (26.2)
22 (16.9)
74 (56.9)

7 (21.9)
5 (15.6)
20 (62.5)

16 (12.3)
114 (87.7)

4 (12.5)
28 (87.5)

51 (39.2)
79 (60.8)

14 (43.8)
18 (56.5)

82 (63.1)
48 (36.9)

23 (71.9)
9 (28.1)

99 (76.2)
31 (23.8)

18 (56.2)
14 (43.8)

117 (90.0)
13 (10.0)

30 (93.8)
2 (6.2)

45 (34.6)
58 (44.6)

13 (40.6)
12 (37.5)

77
60
13
37

15 (46.9)
14 (43.8)
3 (9.4)
16 (50.5)

0.22
0.81
0.92
0.54

24 (75.0)
19 (59.4)
7 (21.9)
8 (25.0)
4 (12.5)
3 (9.4)
2 (6.3)

0.40
0.39
0.12
0.26
0.39
0.23
0.61

0.30

0.54

0.89

0.52
0.34
0.55
0.33
0.36
0.54
0.46
0.11

0.11

0.44

0.52

0.65

0.33

0.54

0.46

0.15

(59.3)
(46.2)
(10.0)
(28.5)

103 (79.2)
66 (50.7)
38 (29.2)
20 (15.4)
24 (18.5)
22 (16.9)
5 (3.8)

LM, leptomeningeal metastases; KPS, Karnofsky performance status; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor; LANO,
Leptomeningeal Assessment in Neuro-Oncology; ECM, extracranial metastases; BM, brain metastasis; MRI, magnetic resonance imaging. *Missing values: gene mutation status (11.1%
missing), thinprep cytologic test (29.6% missing), brain and spinal MRI (2.4 % missing).

Frontiers in Oncology | www.frontiersin.org

4

June 2022 | Volume 12 | Article 903851

Zhang et al.

A 2022 molGPA Model

signiﬁcant differences in sex, age, smoking status, clinical
symptoms, KPS, gene mutation status, LANO neurological
assessment, ECM, BM, controlled primary tumor, TCT, and
brain or spinal MRI between the training and validation sets. The
median time from NSCLC to LM diagnosis was 10 (range: 0-120)
months and 6 (range: 0-100) months in the two cohorts,
respectively. Missing values of gene mutation status (11.1%
missing), lumbar puncture pressure (29.6% missing), CSF
white blood cells (29.6% missing), protein (29.6% missing),
and glucose (29.6% missing) were imputed.

EGFR/ALK alterations were detected in of 103/132 and of 25/
32 patients in the two cohorts, respectively. Among those who
received EGFR-TKI or ALK-TKI therapy after LM diagnosis,
some patients (45/103 and 13/25) received ﬁrst- or secondgeneration TKIs (geﬁtinib, erlotinib, icotinib, afatinib,
crizotinib, alectinib, and ceritinib), while other patients (58/103
and 12/25) received third-generation TKIs (osimertinib
and lorlatinib).

Treatment

As shown in Table 2, the univariate Cox proportional hazard
regression models showed that age, KPS, controlled primary
tumor, gene mutation status, CSF chloride, LANO neurological
assessment, and TKI therapy line were signiﬁcantly associated
with OS (all with p < 0.05). There was no signiﬁcant correlation
between ECM, BM, MRI, and CSF white blood cells, protein

Survival Analysis via Cox Regression
Model

As shown in Table 1, prior to LM diagnosis, 77/130 and 15/32
patients had undergone TKI therapy, 60/130 and 14/32 patients
received cytotoxic chemotherapy, and 37/132 and 16/32 patients
initially diagnosed with LM did not receive any treatment in the
two cohorts, respectively.

TABLE 2 | Univariate and multivariate Cox regression analysis of overall survival of the training set.
Variables

Model
Univariate analysis

Multivariate analysis

HR (95% CI)
Age, year
>65
≤65
Sex
Male
Female
KPS
<60 (reference level)
60-70
80-100
Concurrent BM
No
Yes
Number of BM
Concurrent ECM
No
Yes
Controlled primary tumor
No
Yes
Mutation status
No mutation
EGFR/ALK mutation
LANO neurological assessment
CSF analysis
Chloride
Thinprep cytologic test
Brain and spinal MRI
Negative
Positive
TKI therapy line
No therapy
1st or 2nd
3rd

p value

1 [Reference]
0.63 (0.41, 0.96)

0.03

1 [Reference]
0.88 (0.59, 1.32)

0.53

1 [Reference]
0.39 (0.25, 0.63)
0.21 (0.12, 0.36)

<0.01
<0.01

1 [Reference]
0.92 (0.61, 1.38)

0.67

0.97 (0.88, 1.06)

0.46

1 [Reference]
1.26 (0.70, 2.26)

0.44

1 [Reference]
0.55 (0.36, 0.84)

HR (95% CI)

1 [Reference]
0.96 (0.60, 1.53)

p value

0.88

1 [Reference]
0.47 (0.22, 1.00)

<0.05

0.01

1 [Reference]
0.66 (0.40, 1.06)

0.09

1 [Reference]
0.45 (0.27, 0.77)

<0.01

1 [Reference]
2.05 (0.73, 5.77)

0.26

1.13 (1.10, 1.17)

<0.01

1.12 (1.06, 1.17)

<0.01

0.97 (0.95, 1.00)
1.00 (0.99, 1.01)

0.05
0.08

1 [Reference]
1.04 (0.54, 2.01)

0.91

1 [Reference]
0.52 (0.30, 0.90)
0.31 (0.18, 0.54)

<0.01
<0.01

0.24 (0.08, 0.71)

0.01

LM, leptomeningeal metastases; KPS, Karnofsky performance status; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor; LANO,
Leptomeningeal Assessment in Neuro-Oncology; ECM, extracranial metastases; BM, brain metastasis; MRI, magnetic resonance imaging.
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TABLE 3 | The scoring criteria of the 2022 novel molGPA.

levels, glucose levels and OS (p > 0.05). With the signiﬁcant
variables identiﬁed by the univariate Cox model, we further ﬁtted
the multivariate Cox model and found that KPS (HR = 0.47, 95%
CI [0.22, 1.00], p=0.046), LANO neurological assessment (HR =
1.12, 95% CI [1.06, 1.17], p < 0.001), and TKI therapy (HR =
0.24, 95% CI [0.08, 0.71], p = 0.01) were signiﬁcantly associated
with OS in patients with LM. Controlled primary tumors may be
a signiﬁcant factor for OS (HR = 0.66, 95% CI [0.40, 1.06], p =
0.09), with a p-value at the boundary. However, gene mutation
status was not statistically signiﬁcant in the multivariate Cox
model (p = 0.26). Considering the correlation between gene
mutation status and TKI therapy line (3, 4), we ﬁtted the
multivariate Cox model again by including the gene mutation
status only (Supplemental Table 4). The results showed that the
p-value of the gene mutation status was 0.07.

Prognostic Factor

0
Controlled primary tumor
KPS
LANO neurological assessment
TKI therapy line

No
<60
≥6
No

0.5
Yes
60-70
3-5
1st and 2nd

1
NA
80-100
≤2
3rd

GPA, graded prognostic assessment; KPS, Karnofsky performance status; LANO,
Leptomeningeal Assessment in Neuro-Oncology; TKI, tyrosine kinase inhibitor.

assessment ≤2 (HR, 1.12) and 3rd-TKI therapy line (HR, 0.42 vs
no TKI therapy), with higher scores corresponding to better
prognosis. The controlled primary tumor had a smaller effect
size (HR, 0.66), with a maximum score of 0.5. The model had a
maximum score of 3.5; the higher the score, the lower the risk
was. The targeted-therapy-assisted molGPA score was calculated
for each patient and categorized into three groups: molGPA 0
(group 1, high risk), 0.5-1.0 (group 2, mediate risk), and ≥ 1.5
(group 3, low risk). For all the patients, the median OS for the
three subgroups was 1.01 (95% CI [0.09, 3.58]), 1.45 (95% CI
[0.24, 12.09]), and 8.02 (95% CI [0.98, 38.13]) months,
respectively. The Kaplan-Meier curve for predicting the OS
probability of the study population is shown in Figure 3, which
demonstrates signiﬁcant separation among the three groups.

Random Survival Forest Model
A random survival forest model for predicting survival of patients
with lung adenocarcinoma with LM was ﬁtted to validate the
results of the Cox model. As shown in Figure 2, candidate
predictor variables were ranked according to their importance in
terms of prognostic accuracy. Among these variables, the top four
variables, which included KPS, LANO neurological assessment,
TKI therapy line, and controlled primary tumor with p-values less
than 0.05, were consistent with those identiﬁed by the multivariate
Cox proportional hazard regression model.

Model Evaluation

Establishment and Internal Validation of
the 2022 molGPA Model

The previously reported lung-molGPA model (2017) (12) and
molGPA model for LM (2019) (13) were tested in all patients.
The C-index was calculated among the three models by taking
the average of the C-index values from 100 randomly split
training and validation sets. For each split, molGPA scores
and concordance values were calculated. The higher the Cindex, the better the survival time predicted by the model.
The concordance results are shown in Table 4, where the
average C-index of this model on the training set was 0.710
(95% CI [0.69, 0.73]), which is 7.00% higher than that of the

By selecting statistically signiﬁcant variables with the multivariate
Cox and random forest models, we developed a novel molGPA
model (2022) for LM of lung adenocarcinoma cancer using four
parameters: controlled primary tumor, KPS, LANO neurological
assessment, and TKI therapy line (Table 3). Factors with larger
effect sizes were given a maximum score of 1.0, including KPS
from 80 to 100 (HR, 0.47 vs KPS < 60), LANO neurological

FIGURE 2 | The random forest model for predicting survival of lung
adenocarcinoma with LM. LM, leptomeningeal metastases; KPS, Karnofsky
performance status; LANO, Leptomeningeal Assessment in Neuro-Oncology;
TKI, tyrosine kinase inhibitor; CSF, cerebrospinal ﬂuid; GPA, Graded
Prognostic Assessment.

Frontiers in Oncology | www.frontiersin.org

2022 Novel molGPA Scoring Criteria

FIGURE 3 | Kaplan-Meier Curves Showing Survival using the 2022 molGPA
for lung adenocarcinoma with LM. GPA, Graded Prognostic Assessment.
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TABLE 4 | Concordance results of three GPA models.
Models

Training set (95% CI)

Validation Set (95% CI)

Lung-molGPA (2017)
MolGPA for LM (2019)
Novel molGPA (2022)

0.66 (0.64, 0.69)
0.67 (0.65, 0.70)
0.71 (0.69, 0.73)

0.66 (0.56, 0.76)
0.67 (0.58, 0.77)
0.71 (0.63,0.80)

boundary p-value = 0.07 for the gene mutation status was 0.07,
which suggested the possible prognostic value of mutated status
in real-life cohorts. We further found that the TKI therapy line
was a signiﬁcant positive prognostic factor for LM, identiﬁed by
the multivariate Cox and random forest models. The efﬁcacy of
ﬁrst-generation EGFR-TKIs for EGFR+ NSCLC remains poor
because of low CSF penetration (25, 26). Although secondgeneration EGFR-TKIs, such as afatinib, can partially penetrate
the blood-brain barrier, they exhibit no obvious advantages as
treatment for LM (27). Osimertinib, an irreversible thirdgeneration EGFR TKI, is highly effective in both untreated and
previously treated patients with EGFR-mutant NSCLC,
according to several encouraging international clinical trials
(13–15, 28). For ALK+ NSCLC, lorlatinib is a novel, highly
potent, brain-penetrant, third-generation ALK TKI with broadspectrum potency against most known resistance mutations that
can develop during treatment with existing ﬁrst- and secondgeneration ALK TKIs; its efﬁcacy is signiﬁcant in BM and LM
(29). Guttmann DM (30) also proposed that lung-molGPA is the
critical ﬁrst step in accurately deﬁning the prognosis of patients
with gene mutations; however, it also highlights the need for a
prognostic index incorporating the utilization and timing of
targeted therapy. Therefore, we considered that the TKI
therapy line could be used as a signiﬁcant positive prognostic
factor in the prediction of LM.
The second advantage of our proposed molGPA is the use of the
LANO assessment, a signiﬁcant factor commonly used in clinical
practice, which has never been considered by other prediction
models. The LANO scorecard was formed by the Response
Assessment in Neuro-Oncology (RANO) Leptomeningeal
Metastasis Working Group, an international multidisciplinary
group with the goal of improving response criteria and deﬁning
endpoints for neuro-oncology trials (17, 31). Although the LANO
neurological assessment in LM has not yet been validated, the
LANO scorecard generated a proposal for the response assessment
in LM and has been widely used in international randomized
clinical trials, including the BLOOM and AURA studies (5, 14, 15,
31, 32). Patients with LM from lung adenocarcinoma are treated in
different departments, including neurology, oncology, and
respiratory medicine. The LANO assessment (Supplemental
Table 1) is a standardized assessment for neurological
examination in the prediction model and is easily utilized by
neurologists, oncologists, nurses, and physician assistants.
Third, KPS and controlled primary tumors, two clinically
important signiﬁcant prognostic factors, were considered in our
molGPA model. Patients with a KPS score of 80-100 had better
OS than those with KPS of 60-70 and KPS < 60. KPS was
signiﬁcantly associated with survival and was included in all the
prediction models for BM and LM (6–10, 12, 13). A controlled
primary tumor, requiring the estimation of control of systemic
disease, was included in the RPA and basic score for BM
(BSBM) models (6, 7, 18). In the study, controlled primary
tumor had a p-value of 0.09 in the multivariate Cox model
while a boundary p-value between 0.05 and 0.1 indicates weak
evidence or a trend (33, 34). On the other hand, it was
conﬁrmed that in the full set data using random forest model,
controlled primary tumor is signiﬁcant with p=0.04. Because of

LM, leptomeningeal metastases; GPA, graded prognostic assessment.

lung-molGPA (2017) and 5.5% higher than that of molGPA
(2019) models. The C-index of the model on the validation set
was 0.714 (95% CI [0.63, 0.80]), which was 8.3% higher than
that of the lung-molGPA (2017) and 5.9% higher than that of
the molGPA (2019) models.
We also calculated the C-indices of the random survivalforest-derived prognostic model. The C-index for the training set
(80% of the cohort) was 0.722 (95% CI [0.69, 0.74]), and 0.714
(95% CI [0.60, 0.84]) for the validation set (20% of the cohort).
The C-index of the training set was slightly larger (1.7%) than
that of the Cox-based prognostic model. This is because the
prognostic model with the random survival forest method
included all variables listed in Figure 2 rather than only the
top four variables. The C-indices of the validation set of these two
prognostic models (i.e., Cox-based and random-survival-forestbased) were the same (i.e., C-index = 0.714).

DISCUSSION
To the best of our knowledge, this is the ﬁrst attempt to construct
a 2022 targeted-therapy-assisted molGPA for LM of lung
adenocarcinoma using a multivariate Cox proportional hazard
regression model and the random survival forest method. The
molGPA model considered the following four variables:
controlled primary tumor, KPS, LANO neurological
assessment, and TKI therapy line. According to the molGPA
model scores, patients were divided into three groups: 0 for highrisk, 0.5-1.0 for immediate high-risk, and ≥ 1.5 for low-risk. In
both the training and validation sets, patients with an LM
molGPA score ≥ 1.5 (low risk) were more likely to have a
better OS than the other two groups. The C-index values of
the proposed prognostic model for the training and validation
sets were higher than those of the lung-molGPA (2017) and
molGPA (2019) models (12, 13).
Our 2022 target-therapy-assisted molGPA for LM has several
advantages. First, TKI therapy was used instead of gene
mutations. The recent revolution in the treatment of patients
with prognostic biomarkers has resulted in signiﬁcant
improvements in survival outcomes. As earlier mentioned,
molecular markers were included as important factors in the
lung-molGPA (2017) and molGPA (2019) models, and had been
validated by several studies for its prognostic value in real-world
cohorts (12, 13, 23, 24). However, in this study, gene mutation
status was not statistically signiﬁcant in the multivariate
Cox model. Considering the correlation between gene
mutation status and TKI therapy line, we ﬁtted the
multivariate Cox model again by including the gene mutation
status only (Supplemental Table 4). The results showed a
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the above two reasons, we considered controlled primary tumor
as a signiﬁcant factor and incorporated it into the proposed
2022 molGPA model. The controlled primary tumor was
assigned a maximum of 0.5, based on its HR and statistical
signiﬁcance in the molGPA model for LM. Extracranial
metastases were included in the Lung-molGPA (2017) and
molGPA (2019) models (12, 13). However, in this study,
extracranial metastases showed no statistical signiﬁcance in
Cox proportional hazard regression model and random forest
analysis, which may be related to sample bias, requiring further
analysis and veriﬁcation of a larger sample of patients.
Our study had several limitations. First, it was a
retrospective study from a single center and single ethnic
population, which led to incompleteness of some variables.
For example, forty-eight patients did not undergo lumbar
puncture and had no available information on variables such
as protein and white blood cells. However, the sensitivity
analysis showed that excluding variables with missing data
did not change our conclusions. Second, third-generation
TKIs contain different EGFR- and ALK-related drugs, which
may affect the prognostic effect of the TKI therapy line. Third,
this study evaluated only lung cancer, not other solid cancers,
such as melanoma and breast cancer, which are also common in
LM. We intend to validate the 2022 molGPA model for LM
with lung cancer and extend the model to other solid tumors in
the further study.

this study pertinent code is at https://github.com/Penncil/
2022_molGPA.
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CONCLUSIONS
We developed a novel targeted-therapy-assisted 2022 molGPA
model for predicting LM in lung adenocarcinoma by
incorporating a TKI therapy line in addition to a controlled
primary tumor, KPS, and LANO neurological assessment. The
2022 molGPA model has a better prediction performance and is
a substantial update of previous molGPA models (11, 12). The
2022 molGPA model provides a user-friendly tool for estimating
survival of lung adenocarcinoma patients with LM and may be
useful in clinical decision-making and stratiﬁcation of future
clinical trials.
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